Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Visceral fat

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Visceral fat. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2017-003072-31 Sponsor Protocol Number: 2378 Start Date*: 2018-05-15
    Sponsor Name:VU University Medical Center
    Full Title: The effects of sex hormone administration on marrow and visceral adiposity
    Medical condition: Healthy transgender persons (the effect of differences in sex hormones on the amount of bone marrow fat)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000574-38 Sponsor Protocol Number: ESR-15-10882 Start Date*: 2016-08-31
    Sponsor Name:Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III
    Full Title: A 24 week monocentric prospective randomized, placebo-controlled trial to evaluate Efficacy of combination of Exenatide and Dapagliflozin compared to Dapagliflozin and Placebo and its effects on ...
    Medical condition: Efficacy of combination of Exenatide and Dapagliflozin compared to Dapagliflozin and Placebo and its effects on hepatic, myocardial and pancreatic fat distribution in patients with type 2 diabete...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002568-27 Sponsor Protocol Number: PM-C-0172 Start Date*: 2006-05-08
    Sponsor Name:Sanofi-Synthelabo Groupe
    Full Title: A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with...
    Medical condition: Abdominally obese patients with metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DK (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000775-42 Sponsor Protocol Number: RIMON_L_00075 Start Date*: 2007-12-27
    Sponsor Name:University Hospital Tübingen
    Full Title: Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial
    Medical condition: overweight, obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004430-96 Sponsor Protocol Number: 201600107 Start Date*: 2017-12-11
    Sponsor Name:University Medical Center Groningen
    Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk
    Medical condition: Testicular cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017080-41 Sponsor Protocol Number: GWMD09112 Start Date*: 2010-04-19
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease.
    Medical condition: Subjects with fatty liver disease (≥ 5% liver fat levels).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005444-88 Sponsor Protocol Number: TH9507-CTR-1011 Start Date*: 2007-01-16
    Sponsor Name:Theratechnologies Inc.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess A...
    Medical condition: HIV-associated lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024608 Lipodystrophy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004100-35 Sponsor Protocol Number: FSJD-PIOSPIMET-2012 Start Date*: 2012-12-20
    Sponsor Name:Fundació per la Recerca i la Docència Sant Joan de Déu
    Full Title: A prospective, open-label, randomized, two-armed clinical trial to evaluate the efficacy and safety of a combination of ethinyl-estradiol and levonorgestrel versus a low-dose combination of pioglit...
    Medical condition: Ovarian hyperandrogenism
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005092-24 Sponsor Protocol Number: FSJD-PIOSPIMET-2015 Start Date*: 2016-01-22
    Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU
    Full Title: A prospective, open-label, randomized, two-armed clinical trial to evaluate the efficacy and safety of a combination of ethinyl-estradiol and levonorgestrel versus a low-dose combination of pioglit...
    Medical condition: ovarian hyperandrogenism with hyperinsulinaemia
    Disease:
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004620-38 Sponsor Protocol Number: DOLU-FAT Start Date*: 2020-04-09
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: Study to assess the effect of a Darunavir/Cobicistat-based regimen on weight and body composition in HIV-infected subjects who present weight gain during a dolutegravir-based regimen.
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003686-18 Sponsor Protocol Number: GESIDA11720 Start Date*: 2021-04-29
    Sponsor Name:Seimc-Gesida Foundation
    Full Title: DTG/3TC vs. BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial
    Medical condition: HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001611-37 Sponsor Protocol Number: T2F12017 Start Date*: 2019-02-27
    Sponsor Name:Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III
    Full Title: A 52 week prospective randomized controlled study to investigate the effect of intramuscular testosterone undecanoate supplementation vs placebo on intrahepatic fat content in overweight/obese men ...
    Medical condition: hypogonadism, T2DM, prediabetes, overweight, obesity
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005075-40 Sponsor Protocol Number: 2013-005075-40 Start Date*: 2014-04-08
    Sponsor Name:Research Programs' Unit, Diabetes & Obesity, University of Helsinki
    Full Title: The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006766-21 Sponsor Protocol Number: MINI-SPIOMET Start Date*: 2022-09-02
    Sponsor Name:Hospital de Girona Dr. Josep Trueta
    Full Title: Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study.
    Medical condition: Girls with advanced puberty and accelerated bone maturation. Polycystic Ovary Syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10014054 Early puberty LLT
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001176-30 Sponsor Protocol Number: 20167169 Start Date*: 2016-06-15
    Sponsor Name:Clinical Research Institute, HUCH Ltd.
    Full Title: Effects of PCSK9 inhibition by Evolocumab on postprandial lipid metabolism in type 2 diabetes
    Medical condition: type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-011106-42 Sponsor Protocol Number: 2008MZ09B Start Date*: 2009-06-25
    Sponsor Name:Institute for Clinical and Experimental Medicine
    Full Title: Aditive effects of omega-3 polyunsaturated fatty acids and pioglitazone in the treatment of type 2 diabetes mellitus
    Medical condition: The project deals with hummoral and metabolic aspects of insulin resistance (IR), which is assumed to be the basic metabolic disorder which leads to the development of type 2 diabetes mellitus (T2D...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003432-39 Sponsor Protocol Number: D1690L00016 Start Date*: 2014-11-19
    Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
    Full Title: A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with e...
    Medical condition: Obesity defined as body mass index (BMI) 30-45 kg/m2 Obesity related metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003862-15 Sponsor Protocol Number: 2013-601 Start Date*: 2013-11-19
    Sponsor Name:Jens Faber
    Full Title: Liraglutide in Polycystic Ovary Syndrome A randomised, double-blind, placebo-controlled study of the effect of Liraglutide in Polycystic ovary syndrome on risk markers of vascular Thrombosis
    Medical condition: Polycystic Ovary Syndrome (PCOS), especialy signs of early cardiovascular disease in women with PCOS.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-003395-22 Sponsor Protocol Number: W3600586 Start Date*: 2008-09-04
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: The Effects of Weight Reduction with Orlistat vs. Placebo on Changes in Body Composition
    Medical condition: Weight Loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003430-85 Sponsor Protocol Number: OBERAL Start Date*: 2017-11-29
    Sponsor Name:Helsinki University Hospital
    Full Title: A randomized, open, parallel design study to evaluate the effect on liver fat, adipose tissue and metabolic parameters when switching a protease inhibitor or efavirenz to once daily raltegravir in ...
    Medical condition: Study subjects are HIV infected patients with BMI>25kg/m2 and who have at least one metabolic syndrome component or a fatty liver disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 16:25:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA